CuraGen Presents Update on Clinical Development Program for,Belinostat ( 706-758-4315 (internationa...)

CuraGen Presents Update on Clinical Development Program for,Belinostat

706-758-4315 (international) Passcode: 2474675 Webcast: Access to the live webcast and presentation are available at http://www.curagen.com

A replay of the conference call will be available starting at 11:30 a.m. Eastern time on Tuesday, June 12, 2007 through Sunday, August 12, 2007 by dialing 800-642-1687 (domestic) or 706-645-9291 (international). The passcode for the replay is 2474675. An archive of the webcast will also be accessible at http://www.curagen.com.

Reprints of the poster presentations are available on CuraGen's website at www.curagen.com , or by emailing . info@curagen.com

About Belinostat

Belinostat is a promising small molecule HDAC inhibitor being investigated for its role in the treatment of a wide range of solid and hematologic malignancies either as a single-agent, or in combination with other active anti-cancer agents, including 5-FU, carboplatin, paclitaxel, cis-retinoic acid, azacitidine, doxorubicin and Velcade(R) (bortezomib) for Injection. HDAC inhibitors represent a new mechanistic class of anti-cancer therapeutics that target HDAC enzymes and have been shown to: arrest growth of cancer cells (including drug resistant subtypes); induce apoptosis, or programmed cell death; promote differentiation; inhibit angiogenesis; and sensitize cancer cells to overcome drug resistance when used in combination with other anti- cancer agents.

Intravenous belinostat is currently being evaluated in multiple clinical trials as a potential treatment for multiple myeloma, T- and B-cell lymphomas, AML, mesothelioma, liver, soft tissue sarcoma, colorectal, ovarian cancers, either alone or in combination with anti-cancer therapies. An oral formulation of beli
'"/>

Page: 1 2 3 4 5 6 7 8
Related medicine technology :

1. CuraGen and TopoTarget Announce New Clinical Results With Belinostat to be Reported at Upcoming Major Medical Meetings
2. CuraGen Announces New Preclinical Results with Belinostat and Velafermin to be Presented at AACR Annual Meeting
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
5. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
6. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
7. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
8. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
9. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
10. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
11. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting

Post Your Comments:

(Date:6/19/2013)... June 19, 2013 BioCision , a ... and handling in many areas of medical and ... patents by the U.S. Patent Office that apply ... to standardize sample handling to ensure the consistency ... common laboratory procedures. Patent number ...

(Date:6/19/2013)... , June 19, 2013 /PRNewswire/ -- Chindex International, ... American healthcare company providing services in ... Family Healthcare, a network of private hospitals and ... of its Beijing United Family Rehabilitation Hospital ("BJU ... of the United Family Healthcare ("UFH") network. On ...

(Date:6/19/2013)... , June 19, 2013 DST Health Solutions, ... services to health plans, integrated delivery systems, and health ... Medical Drug Management Service (MDMS) has jumped significantly. ... and automate the pricing of medical prescription drug claims, ... by automating their medical drug claims processes. As specialty ...

Breaking Medicine Technology:BioCision Announces Two New U.S. Patents for Thermo-Conductive Products that Standardize Sample Handling in Laboratory Research 2 Chindex International, Inc. Announces Opening of Beijing United Family Rehabilitation Hospital 2 Chindex International, Inc. Announces Opening of Beijing United Family Rehabilitation Hospital 3 Chindex International, Inc. Announces Opening of Beijing United Family Rehabilitation Hospital 4 Chindex International, Inc. Announces Opening of Beijing United Family Rehabilitation Hospital 5 Demand For DST's Medical Drug Management Service On The Rise As Health Plan Costs Increase 2 Demand For DST's Medical Drug Management Service On The Rise As Health Plan Costs Increase 3

[0] BioCision Announces Two New U.S. Patents for Thermo-Conductive Products that Standardize Sample Handling in Laboratory Research [0] Chindex International, Inc. Announces Opening of Beijing United Family Rehabilitation Hospital [0] Demand For DST's Medical Drug Management Service On The Rise As Health Plan Costs Increase

... NEW YORK, May 24, 2011 Reportlinker.com ... is available in its catalogue: ... Angiogenesis http://www.reportlinker.com/p0284984/Triple-Analysis-Lung-Cancer-Lymphoma-and-Angiogenesis.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ... on cancer drug development strategies in both ...

... YORK, May 24, 2011 Reportlinker.com announces ... available in its catalogue: ... http://www.reportlinker.com/p0284621/Triple-Analysis-Leukemia-Lymphoma-and-Peptides.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ... development strategies in both Leukemia and Lymphoma ...

Reportlinker Adds Triple Analysis: Lung Cancer, Lymphoma and Angiogenesis Reportlinker Adds Triple Analysis: Leukemia, Lymphoma and Peptides

(Date:6/19/2013)... (PRWEB) June 19, 2013 ... of neurologists, neurosurgeons, psychiatrists and urologists with specialists ... The team works with patients and their family ... overall quality of life. Patients also have the ... trials and research. , “Movement disorders can be ...

(Date:6/19/2013)... YOKOHAMA, Japan Leading Japanese pharmaceutical companies, along ... Melinda Gates Foundation, pledged their commitment to bolster ... Health Innovative Technology Fund (GHIT Fund), at a ... the fifth Tokyo International Conference on African Development ... partners including the Ministry of Health, Labour ...

(Date:6/19/2013)... Moffitt Cancer Center and colleagues at Louisiana State University ... that require immediate therapy. It relies on understanding the ... is to better predict a prostate cancer,s aggressiveness to ... published in the online journal PLOS ONE ... accounts for 20 percent of all cancers and 9 ...

(Date:6/19/2013)... 19, 2013 Brightree LLC , ... software solutions for the post-acute care industry, has been ranked ... the Healthcare Informatics 100 (HCI 100) list. This ... the U.S. in terms of revenue during the last fiscal ... rate of 85% annually, and the company has built its ...

(Date:6/19/2013)... City, MO (PRWEB) June 19, 2013 Kansas City ... part of Main Street Day . A section of Main ... pedestrian traffic during the afternoon of the event. The Main ... host the event, which will help Kansas City join the ranks ... used Ciclovia as a tool to foster community vibrancy and active ...

Breaking Medicine News(10 mins):Health News:Abington Memorial Hospital’s Neurosciences Institute Opens Movement Disorders Center 2 Health News:GHIT Fund celebrates historic beginning of Japanese R&D initiative in global health 2 Health News:GHIT Fund celebrates historic beginning of Japanese R&D initiative in global health 3 Health News:Moffitt Cancer Center researchers identify genetic variants predicting aggressive prostate cancers 2 Health News:Brightree Debuts on List of Top 100 Healthcare Technology Companies 2 Health News:Brightree Debuts on List of Top 100 Healthcare Technology Companies 3 Health News:Main Street Corridor Development Corporation and BikeWalkKC Partner to Host Main Street Day and Kansas City’s First Ciclovia 2 Health News:Main Street Corridor Development Corporation and BikeWalkKC Partner to Host Main Street Day and Kansas City’s First Ciclovia 3

[0] Abington Memorial Hospital’s Neurosciences Institute Opens Movement Disorders Center [0] GHIT Fund celebrates historic beginning of Japanese R&D initiative in global health [0] Moffitt Cancer Center researchers identify genetic variants predicting aggressive prostate cancers [0] Brightree Debuts on List of Top 100 Healthcare Technology Companies [0] Main Street Corridor Development Corporation and BikeWalkKC Partner to Host Main Street Day and Kansas City’s First Ciclovia

... access to medical product company,s industry-leading, non-invasive temperature therapy ... ... Tenn., May 29 Adroit Medical Systems, Inc.,today announced its award ... agreement centers on Adroit,s leading,Soft-Temp(R) hypo-hyperthermia blankets, localized heat therapy and ...

... Participating in Outdoor Activities, OFF!(R) Finds ... Uninterrupted, and Your ... sure do know how to make,the most out of their ... their families plan to attend a barbeque,(73 percent), watch fireworks ...

... ... Treatments, LAS ... and marketer of laser, light, and radiofrequency based,aesthetic devices, announced today ... platform for multiple aesthetic laser and,light treatments. The Harmony(XL) can be ...

... May 29 Darwin (NYSE: DR ),is ... product-centric underwriting,divisions, the health care division and the ... ), Under the leadership of senior ... newly created health care division combines all,of Darwin,s ...

... and complex condition that impacts about 15% of the ... known about the mechanisms behind the psychiatric disorder. ... parallels between depressive symptoms and the symptoms of certain ... in Molecular Psychiatry, researchers from University of Miami found ...

... to Cover ... Lost Income, NEW YORK, ... that U.S. employees are just,as concerned about the possibility of losing their ... to a recent survey,from Berkshire Life Insurance Company of America (Berkshire), a,wholly-owned ...

Adroit Medical Systems Awarded Premier Supplier Contract for Temperature Therapy Systems Keep Your Cool and Sanity This Summer!Alma Lasers Announces FDA Clearance of the Harmony(XL) Multi-Application System at THE Aesthetic Show 2008 Darwin Announces Creation of New Health Care and Errors and Omissions Divisions Inflammation, depression and antidepressant response: Common mechanisms Guardian Survey: Fear of Losing Income Due to the Economy Equals Fear of Losing Income Due to Disability

Colloidal Gold Conjugated, Goat anti-human IgG (H&L) - 50 OD...

Colloidal Gold Conjugated, Goat anti-human IgA (Alpha Chain) - 50 OD...

Polyester ribbons (3) impregnated with different OD values of conjugated Protein A...

Polyester ribbon impregnated with conjugated Protein A - .13 OD per sq. cm....

Medicine Products:

Goat Anti-Human IgG (H & L) Antibody, Colloidal Gold Conjugated, 50 OD Goat Anti-Human IgA, alpha chain Antibody, Colloidal Gold Conjugated, 50 OD Protein A Sample Pack - .13 OD ; .25 OD; .50 OD per sq. cm Protein A, Gold Ribbon - .13 OD per sq. cm.